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Infection of genetically susceptible C57BL/6 mice with the LP-BM5 isolate of murine retroviruses causes
profound splenomegaly, hypergammaglobulinemia, lymphadenopathy, and an immunodeficiency syndrome
which includes the development of terminal B-cell lymphomas. Because many of these and the other mani-
festations of LP-BM5 virus-induced disease are similar to those seen in AIDS, this syndrome has been named
murine AIDS, or MAIDS. Previous reports have shown that the onset of MAIDS depends on the presence of
both CD41 T cells and B cells and have suggested that CD41 T-cell-B-cell interactions are important to disease
pathogenesis. Here, we assessed the possibility that interactions between CD40 and its ligand on activated
CD41 T cells, CD40 ligand/gp39, are involved in the development of MAIDS. To test this hypothesis, LP-BM5-
infected B6 mice were treated in vivo with anti-gp39 monoclonal antibody. As a result, MAIDS-associated
splenomegaly, hypergammaglobulinemia, germinal center formation, and the loss of in vitro responsiveness to
the T- and B-cell mitogens concanavalin A and lipopolysaccharide were inhibited. Anti-gp39 monoclonal
antibody-treated LP-BM5-infected mice were also able to mount essentially normal alloantigen-specific cyto-
lytic T-lymphocyte responses. These results support the possibility that molecular interactions between CD40
and gp39 are critical to the development of MAIDS.
A murine retrovirus isolate, LP-BM5, causes a murine im-
munodeficiency syndrome in certain mouse strains, such as the
highly susceptible C57BL/6 strain. LP-BM5 is a retrovirus com-
plex containing a mixture of murine leukemia viruses, includ-
ing ecotropic, recombinant mink cell cytopathic focus-inducing
virus and replication-negative defective viruses, with the de-
fective genome serving as the proximal agent causing the im-
munodeficiency (3, 7, 15, 17, 29). Because many of the disease
features of the LP-BM5-induced syndrome resemble those oc-
curring in human AIDS, this retroviral disease has been
termed mouse AIDS, or MAIDS. Included among the similar-
ities are hypergammaglobulinemia, splenomegaly, and lymph-
adenopathy; dependence of the disease on CD41 T cells;
severely depressed T- and B-cell responses; increased suscep-
tibility to infection, disease progression, and death when ex-
posed to environmental pathogens that normally cause limited
infections; and the development of terminal B-cell lymphomas
(4, 6, 22, 23, 25, 27, 28, 30, 34, 44).
Studies have shown that the induction of MAIDS by LP-
BM5 depends on the presence of both CD41 T cells and B
cells (6, 44). Experiments involving in vivo depletion of CD41
T cells rendered LP-BM5-infected genetically susceptible mice
resistant to the development of MAIDS (44). In vivo studies
have also shown that mice depleted of B cells from birth by the
administration of rabbit antibodies to immunoglobulin M
(IgM) and then infected with the LP-BM5 virus failed to de-
velop MAIDS (6). In keeping with the requirement for B cells
for disease, B cells have been shown to be the primary cell type
for expression of the defective retrovirus after virus infection
(18). Furthermore, in vitro studies have shown that the
MAIDS B6-1710 terminal B-cell lymphoma expresses an anti-
gen(s) that exhibits the properties of a superantigen in that
B6-1710 cells stimulate naive T cells bearing certain Vb T-cell
receptors to proliferate (19). Evidence was provided that was
consistent with the possibility that this superantigen-like activ-
ity might be encoded by the Pr60gag of the defective virus of the
LP-BM5 virus mixture, and it was suggested that defective
virus-infected B cells present this superantigen during the
course of LP-BM5 infection and that the ensuing response is
important to the initiation of MAIDS (19). Although subse-
quent reports have questioned the superantigen activity of the
defective gag protein and have suggested a more complex pic-
ture for superantigen-like phenomena associated with MAIDS
(13, 16, 21, 24, 26, 27, 31, 39), the lack of an agreed upon
identity for the superantigen does not compromise support for
the requirement for lymphoid cellular interactions in MAIDS.
In keeping with the concept of CD41 T helper (Th) cell-B-cell
interactions that are important to disease pathogenesis, in vivo
experiments have shown that CD41 T cells are necessary for
the induction of B-cell activation and differentiation to Ig se-
cretion in MAIDS (44). In addition, results from a recent
report with mice that are major histocompatibility complex
class II negative as a source of B cells, with or without trans-
ferred CD41 T cells, were consistent with a requirement for Th
cell recognition of B-cell class II presented antigen for the
induction of MAIDS (12).
Recently, much has been published about CD41 T-cell in-
teractions with and stimulation of B cells via B-cell CD40 and
its ligand (gp39/CD40L) on activated CD41 Th cells. Ligation
of CD40, a 50-kDa membrane protein expressed on both im-
mature and mature B lymphocytes, induces an activation signal
in a large number of B cells (41). gp39/CD40L has been shown
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to be transiently expressed on CD41 T cells after activation
through the T-cell receptor for antigen (2, 33). A large number
of studies have shown that gp39/CD40 interactions are cru-
cially important to a number of immunologic responses (1, 20,
36). On the basis of requirements for both CD41 T cells and B
cells for LP-BM5-induced MAIDS as described above, it seems
possible that gp39/CD40 interactions are also important to the
induction of this disease and that by interfering with this mo-
lecular interaction, the course of MAIDS might be altered.
Here, we addressed this question by treating LP-BM5 virus-
infected C57BL/6 mice with anti-gp39 monoclonal antibody
(MAb). Various immune parameters were then assessed to
determine if the B-cell activation and hypergammaglobulin-
emia, if not the immunodeficiency per se, of MAIDS were
affected by such anti-gp39 therapy.
C57BL/6 mice were infected on day 1 intraperitoneally with
0.2 ml of LP-BM5 virus, prepared as described by Klinken et
al. (22) and quantitated by XC plaque assay (38) to contain 4
3 105 PFU/ml. On days 1, 3, 5, and 7, LP-BM5-infected mice
received 250 mg of either anti-gp39 MAb or hamster Ig (HIg),
utilizing similar peaks purified by ion-exchange high-perfor-
mance liquid chromatography from ascites obtained from
SCID mice given hybridoma cells (33) or from hamster serum
(Accurate Chemical and Scientific Corp., Westbury, N.Y.),
respectively. Another control group of mice received only anti-
gp39 MAb.
Sera were obtained from these mice at various subsequent
time points and were assayed by enzyme-linked immunosor-
bent assay (ELISA) to assess IgM and IgG2a levels, by use of
affinity-purified goat anti-mouse IgM and IgG2a capture anti-
bodies, alkaline phosphatase-labeled goat anti-mouse Ig
(Southern Biotechnology Associates), and p-nitrophenyl phos-
phate substrate (Sigma, St. Louis, Mo.), with quantitation at
405 nm by an ELISA reader (Dynatech Laboratories, Inc.,
Alexandria, Va.). IgM and IgG2a levels have been reported to
be considerably elevated as early as 3 weeks post-LP-BM5
infection (29, 34), and thus determination of these serum Ig
levels provided a convenient measure of the B-cell activation
and hypergammaglobulinemia associated with MAIDS. At 3,
4.5, and 6 weeks post-LP-BM5 infection, IgM and IgG2a levels
of the LP-BM5 infected mice were found to be severalfold
greater than those of normal mice, whereas mice that received
virus and the anti-gp39 MAb had IgM and IgG2a values ap-
proximating those of normal controls (Fig. 1 [see the legend
for statistical significance]). Infected mice that received HIg, in
contrast, displayed elevated serum Ig levels equal to, if not
above (in the case of IgM due to a cross-reactivity of HIg with
the goat anti-mouse IgM capture antibody), those observed in
mice receiving LP-BM5 alone. We found the same pattern of
results in three other experiments.
Histological studies have shown that early in the course of
infection (2 to 3 weeks), spleens from LP-BM5-infected mice
contain enlarged follicles made up of immunoblasts, plasma,
and plasmacytoid cells (15, 27). In keeping with this finding,
our data above, and the established parameters of B-cell acti-
vation and hypergammaglobulinemia in MAIDS, we found in
a preliminary experiment that splenic sections obtained from
mice that had received LP-BM5 virus 12 days previously
stained positive for many germinal centers (data not shown). In
further experiments designed to evaluate the effect of treat-
ment with the anti-gp39 MAb on germinal center formation in
LP-BM5-infected mice, LP-BM5 virus was given on day 1,
followed by the same course of anti-gp39 MAb or HIg de-
scribed above. On day 13, splenic tissue sections were fixed
with acetone, incubated with peanut agglutinin-biotin followed
by avidin-horseradish peroxidase, and stained with diamino-
benzidine (Sigma). Consistent with our data on serum hyper-
gammaglobulinemia (Fig. 1), tissue sections from virus-in-
fected, anti-gp39-treated mice showed little or no germinal
center formation (Fig. 2B). Conversely, splenic sections from
mice that received LP-BM5 virus and HIg had many germinal
centers (Fig. 2A), defined as containing clusters of peanut
agglutinin-binding, activated B cells, in contrast to poorly pea-
nut agglutinin-binding resting follicular B cells (5, 9, 11, 32,
37).
A very prominent feature of MAIDS is splenomegaly (4, 22,
23, 25, 27–30, 34, 44). Thus, the spleen weights of individual
mice sacrificed between 8 and 10 weeks after LP-BM5 virus
infection from two separate experiments are shown in Fig. 3.
Mice from the two regimens that received either LP-BM5 virus
alone or LP-BM5 plus HIg, had spleens weighing approxi-
mately four to six times those of normal, or anti-gp39 MAb-
treated but uninfected B6 mice. In sharp contrast, the LP-
BM5-infected and anti-gp39-treated mouse groups had spleen
weights approximating the normal values, although there was
some mouse-to-mouse variation, with one of seven mice dis-
playing a somewhat enlarged spleen. The spleen weights of
FIG. 1. MAIDS-associated hypergammaglobulinemia is inhibited by anti-
gp39 treatment of C57BL/6 mice. LP-BM5 virus and anti-gp39 MAb or HIg were
given as indicated in the text. Serum, obtained from mice at 4.5 weeks postin-
fection with LP-BM5 virus, was diluted 1:5,000 and 1:10,000 in phosphate-
buffered saline before analysis. Each pair of solid and shaded bars represents
serum values obtained from an individual mouse such that there are four mice
per group (experiment 2 as defined in the legend to Fig. 3). This experiment is
representative of three other experiments. a, Significantly different from the
value for no infection by the Student t test (P, 0.01); b, not significantly different
from the value for no infection (P . 0.05); c, significantly different from the
values for untreated LP-BM5 infection and LP-BM5 infection treated with HIg
(P , 0.01); d, not significantly different from the value for LP-BM5 infection (P
. 0.05); e, significantly different from the value for LP-BM5 infection (P, 0.01).
However, purified HIg, plated alone as a control, was found to cross-react with
the goat anti-mouse IgM capture antibody. Therefore, the serum IgM values
obtained from the LP-BM5, HIg-inoculated group of mice appear to be elevated
relative to those of mice given LP-BM5 only, but this is artifactual because of the
presence of the HIg (bottom panel).
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FIG. 2. In vivo treatment of LP-BM5-infected C57BL/6 mice with anti-gp39 MAb prevents the formation of germinal centers (gc). Mice (three per group) were
given LP-BM5 virus on day 1 and 250 mg of anti-gp39 MAb or HIg on days 1, 3, 5, and 7. On day 13, immunohistochemistry of splenic sections from LP-BM5-infected
mice treated with HIg displayed many germinal centers made up of clusters of peanut agglutinin-staining B cells (A) Tissue sections from LP-BM5-infected mice
receiving anti-gp39 therapy showed little or no evidence of germinal center formation (B).
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anti-gp39-treated, LP-BM5-infected mice were significantly
different from those of both infected, nontreated and infected,
HIg-treated mice (Fig. 3, legend), and this pattern of results
was also observed in a third experiment.
To measure the effect of anti-gp39 MAb treatment on LP-
BM5-induced immunodeficiency, a variety of immune re-
sponses were monitored, including reactivity to the mitogens
concanavalin A (ConA) and lipopolysaccharide (LPS). Briefly,
4 3 105 spleen cells from individual normal and experimental
mice were cultured with either 10 mg of LPS per ml or 2 mg of
ConA per ml (Sigma), and proliferation was assessed after 72
h by pulsing of the cells with 1 mci of [3H]thymidine (Dupont,
NEN Research Products, Boston, Mass.). In two experiments,
it was found that the response of spleen cells to the T-cell
mitogen ConA was essentially eliminated in mice receiving
only LP-BM5 virus or LP-BM5 plus HIg. In contrast, mice
receiving virus and the anti-gp39 MAb were able to mount a
response equal to about 50 to 60% of that displayed by either
normal C57BL/6 controls or C57BL/6 mice that received only
anti-gp39 MAb, but statistically different from the diminished
responses exhibited by mice that received LP-BM5 virus only
or LP-BM5 plus HIg (Fig. 4 [four mice per group, representing
the same mice as those of experiment 2 of Fig. 3]). In the same
two experiments, we also evaluated the response to the B-cell
mitogen LPS (not shown). As with the response to ConA,
LP-BM5 virus infection caused a dramatic loss of response to
this mitogen. Again, spleen cells from mice receiving not only
LP-BM5 virus but also anti-gp39 MAb demonstrated substan-
tially restored LPS-responsive B cells, compared with those of
mice who received only LP-BM5 or LP-BM5 plus HIg. In one
experiment, the restoration of the LPS response was complete,
reaching the levels of stimulation observed for untreated
C57BL/6 mice. In the other experiment, restoration was to the
levels of the LPS response of cells from uninfected mice
treated only with anti-gp39 MAb, which were somewhat lower
than those of unmanipulated control mice. All mice from this
anti-gp39 control group displayed normal spleen size, a cellular
response to ConA, and the ability to generate an allogeneic
cytolytic T-lymphocyte (CTL) response. Thus, anti-gp39 MAb
therapy largely restored both T-cell and B-cell mitogen re-
sponses in LP-BM5-infected, MAIDS-susceptible C57BL/6
mice.
At 8 weeks post-virus infection, C57BL/6 mice from all in-
oculation regimens were also tested for their ability to mount
allogeneic CTL responses. Spleen cells were cultured with ir-
radiated LB27.4 (H-2bd) B-cell hybridoma cells and assayed 6
days later with 51Cr-labeled P815 (H-2d) mastocytoma cells as
targets. As seen in Fig. 5 (depicting the mice from experiment
2 of Fig. 3), effector cells from all mice who received LP-BM5
virus and anti-gp39 MAb showed allogeneic lytic activity equal
to that of either normal mice or of the C57BL/6 mice treated
only with the anti-gp39 MAb. The allogeneic CTL response
was markedly suppressed in the mice injected with LP-BM5
alone or with LP-BM5 virus and HIg (Fig. 5), although one
mouse of the latter group partially retained the ability to
FIG. 3. In vivo treatment of C57BL/6 mice with anti-gp39 antibody inhibits
MAIDS-associated splenomegaly. Mice received LP-BM5 virus and anti-gp39
MAb or HIg as described in the text. Values, shown as spleen weight in milli-
grams, were obtained on day 56 from individual mice from two separate exper-
iments as follows (from left to right): bars 1 to 3, experiment 1; bars 4 to 7,
experiment 2. a, Significantly different from the value for uninfected mice by the
Student t test (P , 0.001); b, not significantly different from the value for no
infection (P . 0.05); c, significantly different from the values for LP-BM5 infec-
tion and LP-BM5 infection treated with HIg (P , 0.001); d, not significantly
different from the value for LP-BM5 infection (P . 0.05).
FIG. 4. Response to the mitogen ConA is retained in LP-BM5-infected mice
by in vivo treatment with anti-gp39 MAb. Shown are the mice of experiment 2
(Fig. 3) that received LP-BM5 virus and anti-gp39 antibody or HIg as described
in the text. Spleen cells from individual mice were obtained on day 56 and
assessed for their response to ConA stimulation. All values are shown as delta
counts per minute obtained by subtraction of values for responder cells cultured
in media alone from values obtained when cells were cultured in media contain-
ing ConA. The results of this experiment are representative of a second repeat
experiment. a, Significantly different from the value for no infection by the
Student t test (P , 0.001); b, not significantly different from the values for no
infection (P . 0.05); c, significantly different from the values for LP-BM5 infec-
tion and LP-BM5 infection treated with HIg (P , 0.01); d, not significantly
different from the value for LP-BM5 infection (P . 0.05).
FIG. 5. Allogeneic CTL generation is preserved in LP-BM5-infected
C57BL/6 mice treated with anti-gp39 MAb. Shown are the data for the mice of
experiment 2 (Fig. 3), who were given LP-BM5 virus and anti-gp39 antibody or
HIg as indicated. On day 56, all mice were sacrificed, and spleen cells were
cultured with H-2-mismatched stimulators (H-2bd). Later, a 51Cr release assay
was performed with P815 (H-2d) targets and effector/target ratios of 100:1 (solid
bars) and 20:1 (shaded bars). Each pair of bars represents values for percentage
of lysis obtained with effector cells derived from an individual mouse. The
percentage of spontaneous release for the P815 targets was 10%. a, Significantly
different from the value for no infection by the Student t test (P , 0.05); b, not
significantly different from the value for no infection (P . 0.05); c, significantly
different from the values for LP-BM5 infection and infection treated with HIg (P
, 0.05); d, not significantly different from the value for LP-BM5 infection (P .
0.05).
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mount an allospecific CTL response. The resistance of one of
four HIg-treated control mice to LP-BM5-induced depression
of CTL responsiveness is perhaps explainable by the published
observation that allogeneic responses are relatively more re-
sistant to disease pathogenesis than, for example, mitogen re-
activity and major histocompatibility complex-restricted
responses (6, 14, 28). This pattern of substantial restoration of
allogeneic CTL responsiveness in LP-BM5-infected mice by
anti-gp39 MAb, but not HIg, treatment was observed in two
repeat experiments.
These results are consistent with a requirement for an inter-
action between the B-cell signaling molecule CD40 and its
ligand, gp39, on activated Th cells for the development of
MAIDS. An alternative explanation that the anti-gp39 MAb
simply removes CD41 Th cells that have been shown to be
necessary for MAIDS induction (12, 44) seems unlikely for the
following reasons. First, after in vivo anti-gp39 administration,
antigen-specific Th cells from anti-gp39-treated immune ani-
mals readily transfer helper function to recipients (10). This
result indicates that Th cells are neither functionally silenced
nor physically deleted as a consequence of in vivo anti-gp39
administration. Second, in situ, the frequencies of interleukin
2-, interleukin 4-, and gamma interferon-producing T cells in
immune mice are identical to those in anti-gp39-treated or
untreated mice, thus demonstrating that anti-gp39 does not
interfere with the frequency of lymphokine-producing cells
(42). Third, in vivo administration of anti-gp39 does not di-
minish the humoral response to T-cell-independent antigens, a
response shown to be dependent on endogenous T-cell lym-
phokine production for maximal responsiveness (10, 42).
Fourth, previous observations have shown that in vivo anti-
gp39 does not diminish the in vitro proliferative response of
lymph node T cells to challenge with antigen, which suggests
that anti-gp39 does not exert a negative signal to and does not
block the expansion of antigen-specific T cells (32a). Finally, in
preliminary experiments, we compared the extent of LP-BM5
virus-induced immunodeficiency in homozygous gp39/CD40L
knockout (2/2) mice with that in heterozygous gp39/CD40L
knockout (1/2) mice carrying a single copy of the gene by
monitoring several immune responses known to be indepen-
dent of the expression of gp39/CD40L in normal mice. The
data from assessment of splenomegaly, ConA responsiveness,
LPS responsiveness, and the generation of allospecific (H-2b
anti-H-2d) CTLs indicated that 1/2 but not 2/2 knockout
mice were susceptible to LP-BM5-induced MAIDS. Because
the gp39/CD40L molecule is not expressed in the 2/2 mice,
but otherwise functional T and B lymphocytes are present (as
evidenced by the positive immune responses seen here and in
reference 43), these data were incompatible with a mechanism
involving anti-gp39 MAb depletion of CD41 T cells as an
explanation for the MAb therapy experiments discussed above.
As to the precise mechanism by which a disruption of gp39/
CD40 interaction inhibits LP-BM5 virus-induced MAIDS
pathogenesis, a simple, although unlikely, explanation would
be the inhibition of virus infectivity. We feel that this is not the
case. First, in the germinal center experiment mentioned
above, an additional group of mice received LP-BM5 virus on
day 1, followed by MAb on days 14, 15, and 16 (a total of 750
mg)—i.e., MAb therapy after a time at which we have shown
extensive germinal centers exist in LP-BM5-infected mice (Fig.
2A). The spleens, sectioned and stained on day 21, from mice
receiving LP-BM5 virus with subsequent administration of an-
ti-gp39 antibody showed no or only an occasional remnant of
germinal center formation, whereas on day 21, sections taken
from mice receiving LP-BM5 on day 1 and treated with HIg
still had many germinal centers present. Clearly, at least ini-
tially and subsequently through day 13, virus infection occurred
in these mice, and yet anti-gp39 MAb therapy inhibited this
manifestation of MAIDS. Second, and more incisively, defec-
tive gag mRNA expression has been semiquantitatively as-
sessed by reverse transcriptase PCR. As shown in a represen-
tative experiment (Fig. 6), defective gag mRNA was found not
to vary significantly in spleen cells from LP-BM5-infected, anti-
gp39-treated mice versus that in spleen cells from infected
mice that were either untreated or treated with HIg. The
defective gag mRNA was quantitated by the use of defective
gag-specific PCR primers (12), with specificity verified by size,
differential SmaI restriction endonuclease digestion, and se-
quencing of the PCR product (the latter two properties distin-
guishing defective versus ecotropic helper gag). Quantitation
of defective gag mRNA included normalization to amplifica-
tion of hypoxanthine phosphoribosyltransferase message (12,
40). Specific detection of defective gag was further confirmed
by the failure to amplify mRNA in mice that were uninfected
or were infected by the BM5 ecotropic helper virus only (Fig.
6B). With respect to input cDNA and number of PCR cycles,
the conditions for both defective gag and hypoxanthine phos-
phoribosyltransferase were experimentally verified to be those
that achieved a detectable amount of product that was well
below saturating conditions.
The effectiveness of anti-gp39 MAb therapy in preserving
the ability of LP-BM5-virus infected mice to exhibit nearly
FIG. 6. Anti-gp39 MAb treatment of LP-BM5 virus-infected mice does not
cause substantial inhibition of defective Gag mRNA expression. RNA samples (1
mg) from individual mice were either reacted with reverse transcriptase (RT)
(odd-numbered lanes) or not reacted (even-numbered lanes) as indicated, with
the resulting cDNA product split for amplification by either defective Gag2 or
hypoxanthine phosphoribosyltransferase (HPRT)-specific primers for 25 cycles.
On the basis of size markers, the bands for defective Gag or HPRT product
appeared on a 3% agarose gel at the expected migration points corresponding to
245 and 163 bp, respectively. (A) Lanes 1 to 6 represent samples from three mice
infected with LP-BM5 virus and given anti-gp39 MAb treatment; lanes 7 to 12
correspond to three mice receiving LP-BM5 virus plus HIg. Background sub-
tracted PhosphorImager values for defective Gag, normalized to the HPRT
signal, were 1.7, 1.6, and 1.4, respectively, for lanes 1, 3, and 5 compared with 1.5,
1.8, and 1.4 for lanes 7, 9, and 11. (B) Specificity controls are shown, with lanes
1 to 4 corresponding to two mice infected with BM5 ecotropic helper virus only,
lanes 5 to 8 corresponding to two uninfected mice, and lanes 9 and 10 corre-
sponding to a single LP-BM5-infected mouse. Results are representative of a
total of two to eight mice analyzed for each group with the same results.
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normal levels of serum Ig, spleen weights, responses to mito-
gens, and allogeneic CTL generation appears to confirm the
earlier conclusions that Th cell-B-cell interactions are critical
for MAIDS pathogenesis and provides some mechanistic in-
sight by defining a crucial role for a gp39/CD40 molecular
interaction. In that it has been reported that the defective virus
of the LP-BM5 complex may also be expressed in infected
macrophages (8), it is possible that gp39/CD40 interactions
involving Th cells and CD401 macrophages are important in
MAIDS in addition to, or instead of, Th cell-B-cell interac-
tions. Along these lines, a recent report demonstrated the
importance of CD40 on dendritic cells for the dendritic cell-
dependent infection of CD41 T cells by human immunodefi-
ciency virus. These findings were interpreted to suggest that
human immunodeficiency virus infection in vivo might be de-
pendent in part on interactions between CD40 and CD40L
(gp39) (35). The precise nature of the Th cell-B-cell and/or Th
cell-macrophage interactions, including whether the initial ac-
tivation of Th cells required for gp39 expression is due to
superantigen recognition, will require additional investigation.
A thorough understanding of gp39/CD40 interactions in
MAIDS may provide a useful paradigm to be tested in other
retrovirus-induced immunodeficiencies, including AIDS.
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